YU31101A - Enzimatsko razlaganje selektivnih estrogenskih receptorskih modulatora - Google Patents

Enzimatsko razlaganje selektivnih estrogenskih receptorskih modulatora

Info

Publication number
YU31101A
YU31101A YU31101A YUP31101A YU31101A YU 31101 A YU31101 A YU 31101A YU 31101 A YU31101 A YU 31101A YU P31101 A YUP31101 A YU P31101A YU 31101 A YU31101 A YU 31101A
Authority
YU
Yugoslavia
Prior art keywords
estrogen receptor
receptor modulators
selective estrogen
enzymic resolution
enzymic
Prior art date
Application number
YU31101A
Other languages
English (en)
Inventor
Kevin Kun-Chiun Liu
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU31101A publication Critical patent/YU31101A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01013—Sterol esterase (3.1.1.13)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Predmetni pronalazak se odnosi na postupak za dobijanje 5-supstituisanih-6-cikličnih-5,6,7,8-tetrahidronaftalen-2-ol-skih jedinjenja koja su primenljiva kao estrogenski agonisti.[The invention herewith described relates to a process for preparing 5-substituted-6-cyclic-5,6,7,8-tetrahydronaphthalene-2-ol compounds appropriate for use as estrogenic agonists
YU31101A 2000-05-08 2001-04-26 Enzimatsko razlaganje selektivnih estrogenskih receptorskih modulatora YU31101A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20241800P 2000-05-08 2000-05-08

Publications (1)

Publication Number Publication Date
YU31101A true YU31101A (sh) 2005-07-19

Family

ID=22749787

Family Applications (1)

Application Number Title Priority Date Filing Date
YU31101A YU31101A (sh) 2000-05-08 2001-04-26 Enzimatsko razlaganje selektivnih estrogenskih receptorskih modulatora

Country Status (24)

Country Link
US (3) US6828134B2 (sh)
EP (1) EP1156120B1 (sh)
JP (1) JP2002000293A (sh)
KR (1) KR100488385B1 (sh)
CN (1) CN1322842A (sh)
AR (1) AR031844A1 (sh)
AT (1) ATE346159T1 (sh)
AU (1) AU782597B2 (sh)
BR (1) BR0101802A (sh)
CA (1) CA2346426C (sh)
CZ (1) CZ20011576A3 (sh)
DE (1) DE60124616T2 (sh)
ES (1) ES2274854T3 (sh)
HK (1) HK1040264A1 (sh)
HU (1) HUP0101874A3 (sh)
ID (1) ID30106A (sh)
IL (2) IL168341A (sh)
MX (1) MXPA01004626A (sh)
PL (1) PL347407A1 (sh)
RU (1) RU2213778C2 (sh)
SG (1) SG100688A1 (sh)
TW (1) TWI237059B (sh)
YU (1) YU31101A (sh)
ZA (1) ZA200103666B (sh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CN109750013B (zh) * 2019-03-27 2023-01-13 云南师范大学 一种脂肪酶突变体及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814282A (en) * 1984-05-03 1989-03-21 Abbott Laboratories Centrifuge for two-dimensional centrifugation
US5248609A (en) * 1986-11-13 1993-09-28 Schering Aktiengesellschaft Racemic separation of 7α-acyloxy-6β-hydroxymethyl-2-oxabicyclo[3.]-octan-3-ones by stereospecific enzymatic acylate hydrolysis
DE3638762A1 (de) 1986-11-13 1988-05-26 Schering Ag Racematspaltung von 7(alpha)-acyloxy-6ss-hydroxy-methyl-2-oxabicyclo (3.3.0)octan-3-onen durch stereospezifische enzymatische acylat-hydrolyse
CA1319144C (en) * 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
US5106750A (en) * 1988-08-30 1992-04-21 G. D. Searle & Co. Enantio- and regioselective synthesis of organic compounds using enol esters as irreversible transacylation reagents
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
FR2724184B1 (fr) * 1994-09-05 1997-01-03 Rhone Poulenc Chimie Procede de resolution d'un melange d'alcools stereoisomeres
US5589482A (en) * 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
ZA985217B (en) * 1997-06-17 1999-01-07 Schering Corp Enzymatic kinetic resolution of an intermediate useful for preparing substituted tricyclics
PE20000646A1 (es) 1998-06-16 2000-08-05 Pfizer Prod Inc Terapia de combinacion para la fragilidad musculoesqueletica
ID23459A (id) 1998-08-28 2000-04-27 Pfizer Prod Inc Biotransformasi mikroba
US6180375B1 (en) 1999-08-27 2001-01-30 Pfizer Inc. Microbial biotransformation

Also Published As

Publication number Publication date
IL142881A0 (en) 2002-03-10
JP2002000293A (ja) 2002-01-08
US20020049219A1 (en) 2002-04-25
PL347407A1 (en) 2001-11-19
CN1322842A (zh) 2001-11-21
RU2213778C2 (ru) 2003-10-10
US20070249025A1 (en) 2007-10-25
KR100488385B1 (ko) 2005-05-11
KR20010102942A (ko) 2001-11-17
HK1040264A1 (zh) 2002-05-31
HU0101874D0 (en) 2001-07-30
DE60124616T2 (de) 2007-09-13
IL168341A (en) 2006-08-01
HUP0101874A2 (hu) 2002-03-28
AR031844A1 (es) 2003-10-08
ES2274854T3 (es) 2007-06-01
DE60124616D1 (de) 2007-01-04
BR0101802A (pt) 2001-12-18
TWI237059B (en) 2005-08-01
HUP0101874A3 (en) 2003-06-30
EP1156120A3 (en) 2004-02-18
EP1156120A2 (en) 2001-11-21
MXPA01004626A (es) 2004-09-10
CZ20011576A3 (cs) 2002-02-13
SG100688A1 (en) 2003-12-26
AU4375801A (en) 2001-11-15
US20040176415A1 (en) 2004-09-09
ATE346159T1 (de) 2006-12-15
CA2346426A1 (en) 2001-11-08
IL142881A (en) 2006-08-01
US6828134B2 (en) 2004-12-07
ZA200103666B (en) 2002-11-07
ID30106A (id) 2001-11-08
AU782597B2 (en) 2005-08-11
EP1156120B1 (en) 2006-11-22
US7351567B2 (en) 2008-04-01
CA2346426C (en) 2006-08-01

Similar Documents

Publication Publication Date Title
IL130761A (en) 1-¬2-(6-methoxy-3,4-dihydronaphth-1-yl)phenoxy¾ethyl pyrrolidine derivatives as intermediates for estrogen agonists/antagonists
GR1002697B (el) ΣΥΝΘΕΣΙΣ 3-[4-(2-ΑΜΙΝΟΑΙΘΟΞΥ)-ΒΕΝΖΟΥΛΟ]-2-ΑΡΥΛΟ-6-ΥΔΡΟΞΥΒΕΝΖΟ[b]ΘΕΙΟΦΑΙΝΙΩΝ.
HU9601857D0 (en) New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them
HUP0104280A3 (en) Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors, process for their preparation, medicaments containing them
HK1015788A1 (en) Chiral methylphenyloxazolidinones
CA2360024A1 (en) Process for the preparation of non-steroidal glucocorticoid receptor modulators
GB9826540D0 (en) Process
IL146811A0 (en) Novel method for preparing benzoperhydroisoindole compounds
UA66866C2 (uk) Синтез морфолінових похідних
YU31101A (sh) Enzimatsko razlaganje selektivnih estrogenskih receptorskih modulatora
MY120024A (en) Process for preparation of eprosartan using regioselective protection of 2,4-disubstituted-imidazole intermediates.
AU2001236108A1 (en) Process for preparing unsaturated compounds by pyrolysis
YU70502A (sh) Amorfna modifikacija torasemida
HK1051558A1 (en) Method for the enzymatic resolution of the racemates of aminomethyl-aryl-cyclohexanol derivatives.
ZA200005110B (en) Process for preparing intermediates.
EP0971885A4 (en) METHOD FOR PRODUCING INDAN-LIKE CONNECTIONS
WO2001025236A3 (en) A stereoselective process for the preparation of endo-3-aminoazabicycloalkanes
AU2001250429A1 (en) Method for producing 2-alkyl-3-chlorophenols
HRP20020021B1 (en) Method for preparing 2-(2-arylmorpholin-2-yl)ethanol derivatives and intermediates
YU62800A (sh) Postupak za proizvodnju r-(+)-6- karboksamido-3n-metilamino- 1,2,3,4-tetrahidrokarbazola
MY120806A (en) Improved process for preparing pharmaceutically valuable norbenzomorphane derivatives.
MX9603450A (es) Procedimiento para la obtencion de aminotriazolinas substituidas.
MY123517A (en) Process for preparing 10, 11-methanobenzosuberane derivatives
IN184757B (sh)
MY133085A (en) New 2,3,3a,4,9,9a-hexahydro-8-hydroxy-1h-benz<f>indoles, processes for preparing them and their use as pharmaceutical compositions